Cardiff Oncology Inc. (NASDAQ: CRDF)
$4.2700
+0.0100 ( -3.50% ) 4.4K
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
Market Data
Open
$4.2700
Previous close
$4.2600
Volume
4.4K
Market cap
$283.39M
Day range
$4.2900 - $4.4250
52 week range
$1.4100 - $6.4200
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Dec 18, 2024 |
4 | Insider transactions | 1 | Dec 16, 2024 |
4 | Insider transactions | 1 | Dec 12, 2024 |
8-k | 8K-related | 47 | Dec 10, 2024 |
8-k | 8K-related | 17 | Dec 10, 2024 |
10-q | Quarterly Reports | 51 | Nov 07, 2024 |
8-k | 8K-related | 12 | Nov 07, 2024 |
8-k | 8K-related | 16 | Aug 08, 2024 |
10-q | Quarterly Reports | 52 | Aug 08, 2024 |
4 | Insider transactions | 1 | Jul 01, 2024 |